The research project applies the protocol of the World Health Organisation for screening of cervical cancer, with testing of hrHPV as first screening, followed by Visual Inspection of the cervix with Acetic Acid for hrHPV-positive women and for women with minor lesions thermo-ablation of affected areas. This procedure is applied in Uganda, India and Bangladesh. In Slovakia hrHPV-positive women are offered Pap-smear and for women with Pap IV lis excision.
The project performs community sensitisation and mobilisation in dedicated geographical areas and populations, to inform women and relatives about the importance of screening for cervical cancer. To eligible women self-tests for hrHPV are offered, which can be applied at home and investigated in dedicated field-laboratories. Women who are hrHPV positive are invited for further diagnosis. In Uganda, India and Bangladesh Visual Inspection of the cervix with Acetic Acid is performed. In Slovakia Pap-smear. In case dysplasia is found, further treatment is performed with cryotherapy or thermo-ablation. Cases of suspect invasive cervical cancer are referred to hospitals for diagnosis and treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
30,000
use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
Mpasana
Kakumiro, Uganda
Uptake of hrHPV self-test in community
Percentage of eligible women who take self-test out of women who have been offered self-test for hrHPV
Time frame: One week between approaching eligible women and collecting self-test
Coverage of hrHPV self-test in community
Percentage of women who take self-test out of women in geographical area eligible for self-test for hrHPV.
Time frame: 18 months between start approaching women in geographical area and closing screening operations in that area
Uptake of VIA or Pap-smear of eligible women
Percentage of women who are hrHPV-positive and are invited for VIA or Pap-smear who actually undergo the procedure
Time frame: One month between communicating hrHPV test result and measuring attendance in clinic for VIA or Pap-smear
Implementation fidelity of screening protocol
Percentage of health facilities involved in the research that is capable of performing the screening protocol fully (both human resources capacity as equipment and supplies
Time frame: 24 months between start of preparations of health facilities for cervical cancer screening and measuring capabilities of health facility
Sustainability of screening protocol
Percentage of local, district, regional health organisations involved in the study, that is able to maintain the screening protocol as Integrated part of service delivery
Time frame: 24 months between start of preparations in geographical area and measuring cervical cancer screening policies and practices in organisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Test offers insight into existence of dysplasia of the cervix by colouring the transition area
Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions